CG Oncology (CGON) Profit After Tax (2023 - 2026)

CG Oncology has reported Profit After Tax for 4 years, with the latest figure at -$60.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 74.74% year-over-year to -$60.2 million; the trailing twelve-month figure through Mar 2026 stood at -$186.7 million (down 76.9% YoY), and the FY2025 full-year result was -$161.0 million, down 82.87% from the prior year.
• Profit After Tax for Q1 2026 stood at -$60.2 million, down from -$41.3 million in the prior quarter.
• The five-year high for Profit After Tax was -$8.7 million in Q1 2023, with the low at -$60.2 million in Q1 2026.
• Historically, Profit After Tax has averaged -$27.5 million across 4 years, with a median of -$20.4 million in 2024.
• The largest YoY upside for Profit After Tax was 29.88% in 2025 against a maximum downside of 119.16% in 2025.
• CG Oncology's Profit After Tax stood at -$16.6 million in 2023, then tumbled by 92.07% to -$31.8 million in 2024, then decreased by 29.88% to -$41.3 million in 2025, then plunged by 45.77% to -$60.2 million in 2026.
• The last three Profit After Tax figures came in at -$60.2 million (Q1 2026), -$41.3 million (Q4 2025), and -$43.8 million (Q3 2025), per Business Quant data.